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Abstract
Background We studied whether 2 MHz transcranial
color-coded duplex ultrasound (TCCD), combined with a
second generation ECA, accelerate IV rtPA-thrombolysis
in the acute phase of MCA stroke more than TCCD
monitoring alone.
Methods Non-randomized acute MCA stroke patients
undergoing IV rtPA-thrombolysis and 2 MHZ-TCCD
monitoring over 60 min, with (N = 11) or without (N = 15)
additional continuous ECA (5 ml, SonoVue) perfusion,
were compared. Recanalization of the MCA was measured
pre- and post-thrombolysis with the thrombolysis in brain
ischemia (TIBI) grading system, clinical outcome was as-
sessed at admission and 24 h after treatment using the NIH
stroke scale (NIHSS).
Results Patients who received ECA improved their NI-
HSS significantly more than those who were only TCCD
monitored (Mann–Whitney U = 48.0; P = 0.050), and
their flow signal improved more (Mann–Whitney
U = 40.0; P < 0.03).
Conclusions The results of this pilot study show that in
IV-thrombolysis the use of ECA in addition to TCCD
monitoring lead to a greater immediate clinical improve-
ment and to a better flow signal.
Keywords Stroke  Thrombolysis  Transcranial
ultrasound  Microbubbles
Introduction
Transcranial color-coded duplex (TCCD) which visualizes
basal cerebral arteries and therefore localizes precisely
blood clot site is increasingly used as a diagnostic tool in
the monitoring of acute stroke. Continuous application of
2 MHz TCCD with or without fibrinolytic agent has been
shown to accelerate thrombolysis in acute ischemic stroke
due to middle cerebral artery occlusion [1–3]. Synergistic
effects between microbubbles used as contrast agents and
tissue plasminogen activator (rt-PA) accelerate in vitro
enzymatic fibrinolysis of clots exposed to 2-MHz pulsed-
wave TCCD ultrasound [4]. Furthermore, it has been
shown that continuous monitoring of acute MCA main
stem occlusion using TCCD and intravenously adminis-
tered galactose-based microbubbles echocontrast agent
(Levovist) in a few patients who were treated with IV rt-
PA within 3 h of symptom onset is feasible but suggested a
high rate of asymptomatic hemorrhagic transformation [5].
Recently, a non-randomized study used in patients with
acute stroke due to MCA occlusion galactose-based mi-
crobubbles echocontrast agent (ECA) (Levovist) during
sonothrombolysis. It showed that microbubbles safely
accelerate transcranial Doppler-enhanced thrombolysis in
achieving a significant more complete degree of MCA
recanalization and a trend toward better clinical evolution
and long-term outcome [6].
It has been hypothesized that fluid motion resulting from
ultrasound-induced cavitations could accelerate fibrinolysis
by promoting the transport of activators and plasminogen to
their target sites on fibrin within the clot [7, 8]. Furthermore
it has been shown that ultrasound is able to induce revers-
ible changes in the fibrin mesh by creating microstreams of
plasma through the thrombus and accelerating the transport
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and penetration of tPA into the clot, resulting in a more
complete and faster clot dissolution [8].
We studied whether TCCD ultrasound monitoring
combined with a second generation, phospholipid encap-
sulated sulphur hexafluoride microbubble ECA (Sono-
Vue), accelerates IV rtPA-thrombolysis in the acute
phase of middle cerebral artery (MCA) stroke more than
TCCD ultrasound monitoring alone.
Patients and methods
Patients
The patients in this non-randomized study are those who
received IV-rtPA thrombolysis combined with a 60 min
TCCD pulsed-wave monitoring, with and without echo-
contrast agent perfusion, in whom after 30 min TIBI flow
grades improved by one or more grades or whose TIBI
grade was ‡3 and who, therefore were not candidates for a
combined IV-intraarterial thrombolysis. There were two
groups, one with (11 patients) and one without (15 pa-
tients) additional continuous perfusion of an ECA. The
selection criterion between the two groups was the pres-
ence of unsatisfying (which means that there was still a
weak color-coded duplex signal to allow to depict but not
‘‘to follow’’ the entire vessels of the circle of Willis and
the MCA in particular) temporal bone windows, prompting
the use of ECA. Furthermore, B-mode visualization of the
parenchyma was good enough to recognize plane of in-
sonation (e.g. mesencephalon).
Methods
Imaging
CT-scan, in order to exclude hemorrhage, and CT-angi-
ography were performed prior to thrombolysis in all pa-
tients. Sonographers were blinded to these exams. Control
CT and/or MRI and MR angiography were performed 2–
15 days later.
R-tPA thrombolysis
All stroke patients in this study were treated with 0.9 mg/
Kg TPA (10% bolus) within 3 h of stroke onset.
TCCD examination pre-thrombolysis
In order to assess the exact site of occlusion in the MCA,
three certified sonographers experienced in TCCD throm-
bolysis-monitoring in acute stroke, performed standard
2-MHz TCCD examination in all patients in the emergency
room before tPA administration (Acuson, Sequoia, USA).
At this point, patients with unsatisfying temporal bone
windows received a bolus of 0.1 ml on each temporal side.
According to previous TCCD studies [1, 5], temporal
insonation in the mesencephalic axial plane and B-mode
imaging was performed in all patients in order to visualize
the hyperechogenic lateral fissure anterior and lateral to the
cerebral peduncles. The ultrasound beam was positioned at
the blood flow/thrombus interface. Main stem occlusion of
the MCA was diagnosed when no flow could be demon-
strated despite good visualization of the ipsilateral vessels
of the circle of Willis. Residual blood flow of the MCA,
when present, was assessed with an insonation depth
45–65 mm.
TCCD monitoring
Parallel to the onset of rt-PA treatment, monitoring of the
residual blood flow in the affected MCA was performed in
all patients and those with unsatisfying temporal bone
window received additional ECA continuous infusion. Site
of occlusion on the MCA was defined according to the
thrombolysis in brain ischemia (TIBI) grading system.
Accordingly residual flow was: TIBI 0: absent; TIBI 1:
minimal; TIBI 2: blunted; TIBI 3: dampened; TIBI 4:
stenotic/asymmetric; TIBI 5: normal/symmetric. Partial
recanalization at 24 h was considered when the TIBI grade
evolved from 0–1 to 2–3 and complete recanalization with
a final TIBI grade of 4 or 5 (Fig. 1). Recanalization of the
MCA was recorded by the sonographers (who were blinded
to the NIHSS score) using the TIBI grading system post-
thrombolysis. When there was no residual Doppler signal,
the position of the ultrasound beam was verified every
5 min using B-mode imaging. During recanalization
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Fig. 1 Percentage of degree of recanalization of the MCA (middle
cerebral artery) according to TIBI (thrombolysis in brain ischemia)
criteria after rtPA thrombolysis in group 1 (rtPA-TCCD) and 2 (rtPA-
TCCD-ECA)
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process the ultrasound beam was shifted to maintain it at
the blood flow-thrombus interface. All patients were
monitored with continuous hand-held 2-MHz TCCD
(Pulsed-wave mode power output: 189 mW/cm2 (data from
the manufacturer); sample volume 10 mm; Acuson, Se-
quoia, USA) over 60 min. Gain settings, transmit power,
pulse repetition frequency were adapted individually for an
optimal signal-to-noise ratio. These parameters remained
unchanged during the entire monitoring.
Echocontrast agent
In accordance to the contraindications as stated by EMEA
(European Agency for the Evaluation of Medicinal Prod-
ucts; London 2004), 11 patients with unsatisfying temporal
bone windows received one bolus injection of 0.1 ml on
each temporal side, in order to assess the exact site of
occlusion in the MCA before TCCD monitoring. This
procedure was repeated for control examination at 24 h.
During TCCD monitoring these 11 patients received a
continuous infusion in the cubital vein of a total dose of
5 ml of microbubble phospholipid encapsulated sulphur
hexafluoride echocontrast agent (8 ll/45 lg/ml) over
60 min (SonoVue, Bracco SA, Switzerland).
Clinical outcome
Clinical severity of stroke was assessed in all the patients
using the NIH Stroke Scale (NIHSS) at admission and at
24 h after treatment by a clinician who was blinded to the
ultrasonographic monitoring modality. Clinical improve-
ment was considered when the NIHSS score improved at
24 h of at least ‡4 points.
Results
A total of 15 patients (group 1) (9 men, 6 women; mean
age 65.1 years) underwent IV thrombolysis and TCCD
monitoring over 60 min. 12 patients (75%) had a NIHSS
score ‡10 at admission.
A total of 11 patients (group 2) (6 men, 5 women; mean
age 68.9 years) were treated with IV thrombolysis and
received additional ECA enhanced TCCD monitoring over
60 min. 7 patients (63.6%) had a NIHSS score ‡10 at
admission (Table 1).
Age, sex, IV-thrombolysis mean time at onset, and NI-
HSS score at admission, and initial TIBI grades did not
differ significantly between the two groups.
Residual blood flow in the MCA was evaluated with the
TIBI score pre-thrombolysis, during thrombolysis
(30 min), post thrombolysis (60 min) and at 24 h. 18
patients had a TIBI score pre-thrombolysis <3 (10/15 in
group 1 and 8/11 in group 2). The flow signal (measured
according to the improvement of TIBI grades) improved
more in group 2 than in group 1 after 30 min (Mann–
Whitney U = 40.5; P < 0.03) and remained significant
after 60 min (Mann–Whitney U = 40.0; P < 0.03). Com-
plete recanalization after 1-h systemic thrombolysis oc-
curred in 8 patients in group 1 (median time: 42.25 min)
and in 7 patients in group 2 (median time: 32.85 min). 2
patients suffered from symptomatic hemorrhagic transfor-
mation after treatment: 1 in group 1 (rtPA + TCCD) and 1
in group 2 (rtPA + TCCD + ECA). There was no signifi-
cant difference in the bleeding rate between the two
groups. Group 2 improved the NIHSS significantly more
than group 1 (Mann–Whitney U = 48.0; P = 0.05).
Discussion
There are two main results of the present non-randomized
pilot study. (1) ECA enhanced TCCD monitored rtPA
thrombolysis is superior to TCCD monitored rtPA throm-
bolysis in terms of residual flow improvement as measured
by TIB, especially during the first 30 min. (2) It is also
superior in the immediate (24 h) clinical improvement as
measured by NIHSS. Last but not least, the rate of hem-
orrhagic transformation was not different between the two
groups.
The present study thus confirms with a different echo-
contrast agent (second generation ECA SonoVue versus
Levovist), a different transcranial ultrasound technique
(TCCD versus TCD), and different durations of insonation
(1 vs. 2 h), the results of a recent study showing superior
recanalization by using echocontrast agents in addition to
Doppler monitoring of thrombolysis [6]. Though the exact
mechanisms on the effects of combined TCCD and mi-
crobubbles remain unknown in humans, several experi-
mental studies have demonstrated the ability of ultrasound
routinely used for transcranial diagnostic applications to
potentiate enzymatic thrombolysis [7–11]. Clinical studies
have confirmed these effects in acute stroke patients [2,
12–14]. Moreover, the streaming of microbubbles con-
tained in echocontrast agents driven by ultrasound energy
seems to lead to mechanical damage on the surface of the
thrombus. This increases infiltration of tPA in the thrombus
and thus further accelerates clot dissolution by lowering the
energy needed for cavitation and this even in the absence of
thrombolytic drugs [1, 15–19]. However, there are actually
no data demonstrating that cavitations take place in the
human brain using diagnostic echocontrast enhanced TCD/
TCCD monitoring. The in vivo stability of the echocontrast
agents is related to their shell characteristics and to the
solubility of the gas used in their preparation [20]. Second
generation echocontrast agents such as SonoVue which
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contain poorly soluble gases such as sulphur hexafluoride
agents increase the accuracy in detection of abnormalities
in cerebral arteries by improving the Doppler signal to
noise ratio. They also have a longer action time than air-
containing agents like Levovist [20]. Moreover, they
contain microbubbles with a much smaller diameter than
air-filled microbubbles which improves the passage of the
pulmonary capillary bed [20].
It has been shown in angiographic studies [21, 22] that
IV rtPA is relatively ineffective with a rate of early
recanalization of approximately 25% in patients with large
vessel occlusion such as MCA main stem occlusion. There
is thus a need for additional therapies [23]. Our study has
limitations, it is non-randomized and touches a relatively
small sample size of patients who responded to IV
thrombolysis within 30 min of infusion, but it lends sup-
port to the combined use of Doppler monitoring and
echocontrast agents.
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